Results 201 to 210 of about 365,745 (315)
Taking Action on Concurrent Disorders: Calls for Action on Collaborative Research Priorities in Canada. [PDF]
Little J +14 more
europepmc +1 more source
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
Research priorities in the field of interprofessional healthcare education: a James Lind Alliance Priority Setting Partnership. [PDF]
Kumlien C +7 more
europepmc +1 more source
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou +12 more
wiley +1 more source
Aligning bladder cancer research with patient needs: an update on research priorities. [PDF]
Humayun-Zakaria N +3 more
europepmc +1 more source
Interpreting the effects of DNA polymerase variants at the structural level
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi +7 more
wiley +1 more source
Research priorities in pleural disease: study protocol for a joint patient-provider Delphi consensus statement. [PDF]
Shaw JA +4 more
europepmc +1 more source
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata +10 more
wiley +1 more source
Morphological subphenotypes in acute pancreatitis-related ARDS: limitations, extensions, and research priorities. [PDF]
Pensier J, De Jong A, Jaber S.
europepmc +1 more source

